Topic summary

Tracking semaglutide's approved indications across jurisdictions, dated

Compounds › Semaglutide semaglutide effect size SELECT trial

This is a generated summary. It shows the 5 most-liked posts from a topic of 20, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

preregisteredTL3Research methods8 Apr 2026#1

Tracking semaglutide's approved indications across jurisdictions, dated Writing it up because I had to work it out twice and would rather nobody else did.

I have seen SURMOUNT-OSA (N Engl J Med, 2024) cited in support of a claim I do not think it supports, twice this month, so I would like to work through what it actually shows.

My reading is that the trial is sound for its own question and is being stretched to answer a different one. I might be wrong about that, which is why this is a topic rather than a correction.

What I would like from this discussion: someone who disagrees with me to say why, with the section of the paper they are relying on.

41 likes 4mo

NicolaidesTL3Regular11 May 2026#5

On the opening post — agreed on the reasoning, with one qualification.

The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

16 likes 3mo

c.adebayoTL2 Moderator14 Jun 2026#11

post #10 answers the question as asked. The question underneath it is different.

The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice. Visible particles or frank cloudiness is different and would be reason to contact the supplier.

19 likes 1mo

hana.satoTL4 Moderator4 Jul 2026#15

Staff post. Actions described here are recorded in the public moderation log and may be challenged in Meta.

post #14 is right about the mechanism and I think understates the practical bit.

On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.

13 likes 24d

j.asanteTL2 Moderator8 Jul 2026#16

Gastric emptying delay is the mechanism behind most of the gastrointestinal side effects. Slowing the stomach empties it feeds less food into the intestines at a time, which is part of the satiety mechanism but is also why nausea is dose-dependent and titration-dependent.

27 likes 20d

Read the full topic (20 posts)

Suggested topics

Topic	Participants	Replies	Views	Activity
Is there a ceiling dose beyond which semaglutide stops adding benefit? Compounds › Semaglutide effect size type 2 diabetes SELECT trial Is there a ceiling dose beyond which semaglutide stops adding benefit? I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in…		2	14k	2mo
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold? Compounds › Semaglutide randomised trial type 2 diabetes STEP programme effect size Solved Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SCALE ( N…	+58	62	49k	20mo
Second pass at: Semaglutide and alcohol: what is actually documented Compounds › Semaglutide semaglutide type 2 diabetes effect size randomised trial Closed Second pass at: Semaglutide and alcohol: what is actually documented Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021) cited in…	+15	19	4.4k	13mo
What SELECT changed about how semaglutide is discussed, and what it did not Compounds › Semaglutide STEP programme type 2 diabetes randomised trial Solved Asking directly, because I could not find a straight answer: What SELECT changed about how semaglutide is discussed, and what it did not Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…	+120	132	2k	14mo
Coming back to: Why semaglutide solutions can look faintly opalescent and when that matters Compounds › Semaglutide SELECT trial randomised trial STEP programme Asking directly, because I could not find a straight answer: Why semaglutide solutions can look faintly opalescent and when that matters Comparing SELECT ( N Engl J Med , 2023) with PIONEER 6 ( N Engl J Med ,…	+16	20	17k	13mo

Related topics — sharing the tags semaglutide, effect size, SELECT trial

Topic	Participants	Replies	Views	Activity
Publication bias detection and its low power Evidence › Meta-analyses heterogeneity publication bias effect size On the subject in the title: Publication bias detection and its low power Working notes rather than a conclusion. I have seen SURMOUNT-1 ( N Engl J Med , 2022) cited in support of a claim I do not think it…		2	3.2k	1d
Random versus fixed effects: choosing rather than defaulting Evidence › Meta-analyses effect size publication bias risk of bias heterogeneity Closed Random versus fixed effects: choosing rather than defaulting — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please read it before posting;…	+16	20	22k	13mo
Revisiting: Holding a dose indefinitely: is there a documented downside? Practice › Dosing & titration titration tirzepatide worked example missed dose Solved The question in the title: Revisiting: Holding a dose indefinitely: is there a documented downside? I will give what I have already checked below so nobody repeats it. A question about technique rather than…	+26	30	4.5k	18mo
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just differently reported? Compounds › Tirzepatide tirzepatide SURMOUNT programme effect size randomised trial Solved Tirzepatide and nausea: is the profile genuinely different or just differently reported? I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing STEP 1 ( N Engl J…	+109	122	3.6k	2mo
Coming back to: Prediction intervals and why they are more honest than confidence intervals Evidence › Meta-analyses publication bias heterogeneity effect size risk of bias Prediction intervals and why they are more honest than confidence intervals Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURMOUNT-OSA ( N Engl J Med , 2024)…		2	65	22mo